Lack of efficacy of imatinib in a patient with metastatic Leydig cell tumor.
Imatinib is a tyrosine kinase inhibitor with activity in gastrointestinal stromal tumor and a variety of other solid and hematological malignancies. Studies in vitro and in a mouse model suggested that the imatinib might also be active in malignant Leydig cell tumor. We report on the--to our knowledge--first treatment experiment with imatinib in a patient with metastatic Leydig cell tumor. Unfortunately, the tumor progressed during treatment.
Froehner
Michael
M
Department of Urology, University Hospital, Technical University of Dresden, Fetscherstrasse 74, 01307, Dresden, Germany. Michael.Froehner@uniklinikum-dresden.de
Beuthien-Baumann
Bettina
B
Dittert
Dag-Daniel
DD
Schuler
Ulrich
U
Wirth
Manfred P
MP
D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D000068877:Imatinib Mesylate; D007984:Leydig Cell Tumor / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000556:secondary; D017211:Treatment Failure
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases